Home > Boards > US Listed > Biotechs > Aptinyx Inc. (APTX)

Aptinyx started at outperform with $7 stock price

Public Reply | Private Reply | Keep | Last ReadPost New MsgPrevious | Next
crudeoil24 Member Profile
Member Level 
Followed By 593
Posts 37,829
Boards Moderated 5
Alias Born 12/12/04
160x600 placeholder
Aptinyx to Present at 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. - 12/12/2019 7:07:10 AM
Aptinyx to Present Preclinical Data Exhibiting Effects of NYX-783 in Models of PTSD and Alcohol Use Disorder at the American ... GlobeNewswire Inc. - 12/9/2019 4:05:10 PM
Aptinyx Initiates Phase 2 Study of NYX-458 in Patients with Mild Cognitive Impairment Associated with Parkinson’s Disease GlobeNewswire Inc. - 12/5/2019 6:58:10 AM
Aptinyx to Present at Upcoming Investor Conferences GlobeNewswire Inc. - 11/14/2019 7:57:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/12/2019 4:37:34 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/12/2019 4:34:41 PM
Aptinyx Reports Third Quarter 2019 Financial Results and Highlights GlobeNewswire Inc. - 11/12/2019 4:01:00 PM
Aptinyx Initiates Two Phase 2 Studies of NYX-2925 in Patients with Chronic Centralized Pain Conditions GlobeNewswire Inc. - 11/12/2019 7:27:00 AM
Aptinyx to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019 GlobeNewswire Inc. - 11/5/2019 8:07:00 AM
Aptinyx Announces Results of Phase 2 Fibromyalgia Study of NYX-2925 Have Been Selected for Late-Breaking Presentation at the ... GlobeNewswire Inc. - 10/28/2019 7:57:05 AM
Aptinyx to Present Preclinical Data on Three Clinical-Stage NMDA Receptor Modulators at the 49th Annual Meeting of the Societ... GlobeNewswire Inc. - 10/15/2019 8:46:00 AM
Aptinyx (APTX) Alert: Johnson Fistel Launches Investigation into Aptinyx Inc.; Investors Suffering Losses Encouraged to Conta... PR Newswire (US) - 10/8/2019 9:00:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/7/2019 4:37:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2019 4:36:05 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2019 4:32:11 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2019 4:29:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2019 4:24:03 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2019 4:21:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2019 4:18:07 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/2/2019 4:02:20 PM
Aptinyx to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire Inc. - 9/30/2019 7:03:00 AM
Three Recent Preclinical Publications Highlight NMDA Receptor Activation Facilitated by Aptinyx’s NYX-2925 GlobeNewswire Inc. - 9/26/2019 8:07:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/4/2019 4:33:03 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 9/4/2019 4:31:11 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/4/2019 7:45:16 AM
crudeoil24 Member Level  Friday, 09/13/19 12:06:31 AM
Re: crudeoil24 post# 1
Post # of 2 
Aptinyx started at outperform with $7 stock price target at Wedbush
8:40 am ET September 12, 2019 (MarketWatch)
Share
Print
(END) Dow Jones Newswires

September 12, 2019 08:40 ET (12:40 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

New York Yankees and Duke Basketball
Public Reply | Private Reply | Keep | Last ReadPost New MsgPrevious | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist